Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Amino Acids Année : 2023

Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories

Résumé

Dysregulated human peptidases are implicated in a large variety of diseases such as cancer, hypertension, and neurodegeneration. Viral proteases for their part are crucial for the pathogens' maturation and assembly. Several decades of research were devoted to exploring these precious therapeutic targets, often addressing them with synthetic substrate-based inhibitors to elucidate their biological roles and develop medications. The rational design of peptide-based inhibitors offered a rapid pathway to obtain a variety of research tools and drug candidates. Non-covalent modifiers were historically the first choice for protease inhibition due to their reversible enzyme binding mode and thus presumably safer profile. However, in recent years, covalentirreversible inhibitors are having a resurgence with dramatic increase of their related publications, preclinical and clinical trials, and FDA approved drugs. Depending on the context, covalent modifiers could provide more effective and selective drug candidates, hence requiring lower doses, thereby limiting off-target effects. Additionally, such molecules seem more suitable to tackle the crucial issue of cancer and viral drug resistances. At the frontier of reversible and irreversible based inhibitors, a new drug class, the covalent-reversible peptidebased inhibitors, has emerged with the FDA approval of Bortezomib in 2003, shortly followed by 4 other listings to date. The highlight in the field is the breathtakingly fast development of the first oral COVID-19 medication, Nirmatrelvir. Covalent-reversible inhibitors can theoretically provide the safety of the reversible modifiers combined with the high potency and specificity of their irreversible counterparts. Herein, we will present the main groups of covalent-reversible peptide-based inhibitors, focusing on their design, synthesis, and successful drug development programs.
Fichier principal
Vignette du fichier
HAL_Covalent-reversible peptide-based proteases inhibitors. Design, synthe...tories.pdf (2.47 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04167336 , version 1 (20-07-2023)

Identifiants

Citer

Anthony Feral, Anthony R. Martin, Alexandre Desfoux, Muriel Amblard, Lubomir Vezenkov. Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories. Amino Acids, In press, ⟨10.1007/s00726-023-03286-1⟩. ⟨hal-04167336⟩
11 Consultations
99 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More